[Palliative chemotherapy with 5 FU and CPM in cancer of the prostate with bone metastases resistant to oestrogens. A clinical trial (author's transl)].
The efficacy of an association of cyclophosphamide (CPM) and 5-fluorouracil was studied in 15 patients with prostate cancer not responding to oestrogen therapy, and more particularly its effect on pain due to bone metastases. No objective improvement was noted with this association, but there was a definitite reduction in bone metastases pain in 5 of the patients, with an average remission time of 4 months. Half of the patients had nausea and vomiting, but in spite of this digestive intolerance those patients who obtained pain relief for 4 months considered the treatment to be of positive value. This therapy is recommended only fater the failure of castration, anti-androgens, and oestrogens, together with nitrogen mustard (Estracyt) and corticotherapy.
D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D004967:Estrogens; D003520:Cyclophosphamide; D005472:Fluorouracil
Chimiothérapie palliative par le 5 FU et le CPM dans le traitement due cancer de la prostate avec métastases osseuses résistant aux oestrogènes. Essai clinique.